Published • loading... • Updated
UK Markey’s Denise Fabian: Theranostics lets us pair a diagnostic with a radioactive therapeutic that target the same molecule
Summary by The Cancer Letter
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
UK Markey’s Denise Fabian: Theranostics lets us pair a diagnostic with a radioactive therapeutic that target the same molecule
Theranostics, the pairing of a diagnostic imaging agent with a targeted radiopharmaceutical therapy, has moved from a niche corner of nuclear medicine into one of the most active areas of investment in oncology. Major pharmaceutical companies, including Bristol Myers Squibb, Johnson & Johnson and Eli Lilly, are running development programs. Experts project that within 15 years, 60% of radiation delivered to treat cancer will come from radiophar…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
